Bicycle Therapeutics plc (NASDAQ:BCYC - Get Free Report)'s stock price fell 4.6% during trading on Friday . The company traded as low as $8.27 and last traded at $8.29. 45,076 shares changed hands during trading, a decline of 88% from the average session volume of 388,414 shares. The stock had previously closed at $8.69.
Analyst Ratings Changes
A number of brokerages have recently commented on BCYC. Royal Bank of Canada cut their price objective on Bicycle Therapeutics from $35.00 to $32.00 and set an "outperform" rating for the company in a research report on Friday, May 2nd. Barclays cut their price objective on Bicycle Therapeutics from $40.00 to $15.00 and set an "overweight" rating for the company in a research report on Thursday, May 1st. B. Riley cut their price objective on Bicycle Therapeutics from $17.00 to $14.00 and set a "neutral" rating for the company in a research report on Friday, May 2nd. Needham & Company LLC reissued a "buy" rating and set a $29.00 target price on shares of Bicycle Therapeutics in a research note on Friday, May 2nd. Finally, HC Wainwright reissued a "buy" rating and set a $33.00 target price on shares of Bicycle Therapeutics in a research note on Wednesday, February 26th. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. Based on data from MarketBeat, Bicycle Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $25.00.
Read Our Latest Report on Bicycle Therapeutics
Bicycle Therapeutics Price Performance
The firm has a market capitalization of $579.66 million, a price-to-earnings ratio of -2.54 and a beta of 1.46. The stock has a fifty day moving average of $8.11 and a two-hundred day moving average of $11.33.
Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The company reported ($0.88) earnings per share for the quarter, missing analysts' consensus estimates of ($0.86) by ($0.02). Bicycle Therapeutics had a negative return on equity of 27.35% and a negative net margin of 450.64%. The business had revenue of $9.98 million for the quarter, compared to analyst estimates of $8.67 million. On average, research analysts forecast that Bicycle Therapeutics plc will post -3.06 EPS for the current year.
Hedge Funds Weigh In On Bicycle Therapeutics
Several large investors have recently added to or reduced their stakes in the business. Barclays PLC grew its stake in Bicycle Therapeutics by 878.3% in the 4th quarter. Barclays PLC now owns 2,612 shares of the company's stock valued at $37,000 after purchasing an additional 2,345 shares during the period. Tocqueville Asset Management L.P. grew its stake in Bicycle Therapeutics by 24.5% in the 1st quarter. Tocqueville Asset Management L.P. now owns 18,300 shares of the company's stock valued at $155,000 after buying an additional 3,600 shares in the last quarter. Jane Street Group LLC grew its stake in Bicycle Therapeutics by 18.9% in the 4th quarter. Jane Street Group LLC now owns 23,991 shares of the company's stock valued at $336,000 after buying an additional 3,811 shares in the last quarter. Exchange Traded Concepts LLC grew its position in shares of Bicycle Therapeutics by 90.3% during the 1st quarter. Exchange Traded Concepts LLC now owns 12,764 shares of the company's stock valued at $108,000 after purchasing an additional 6,057 shares in the last quarter. Finally, Bank of America Corp DE grew its position in shares of Bicycle Therapeutics by 2.1% during the 4th quarter. Bank of America Corp DE now owns 392,859 shares of the company's stock valued at $5,500,000 after purchasing an additional 7,994 shares in the last quarter. Institutional investors own 86.15% of the company's stock.
About Bicycle Therapeutics
(
Get Free Report)
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.
Featured Articles
Before you consider Bicycle Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bicycle Therapeutics wasn't on the list.
While Bicycle Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
